Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome

Application of Clinical Genetics

Volumn 9, Issue , 2016, Pages 39-47

  Marshall Gradisnik, Sonya ^a,b   Huth, Teilah ^a,b   Chacko, Anu ^a,b   Johnston, Samantha ^a,b   Smith, Pete ^b   Staines, Donald ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Acetylcholine receptors; Chronic fatigue syndrome; Genotypes; Myalgic encephalomyelitis; Transient receptor potential ion channels

Indexed keywords

CHOLINERGIC RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8;

ACETYLCHOLINE RECEPTOR GENE; ADULT; ARTICLE; CHRNA2 GENE; CHRNA3 GENE; CHRNA5 GENE; CHRNB4 GENE; CHRNE GENE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSIENT RECEPTOR POTENTIAL CHANNEL GENE; TRPC2 GENE; TRPC4 GENE; TRPM3 GENE; TRPM8 GENE;

EID: 84962419780     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S99405     Document Type: Article

References (78)

1. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-469.
2. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-640.
3. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011;11:645-657.
4. Möller MJ, Kammerer R, von Kleist S. A distinct distribution of natural killer cell subgroups in human tissues and blood. Int J Cancer. 1998;78:533-538.
5. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214:73-91.
6. Fan YY, Yang BY, Wu CY. Phenotypically and functionally distinct subsets of natural killer cells in human PBMCs. Cell Biol Int. 2008;32:188-197.
7. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood. 2001;97:3146-3151.
8. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107:159-166.
9. Dustin ML, Long EO. Cytotoxic immunological synapses. Immunol Rev. 2010;235:24-34.
10. Rouvier E, Luciani M, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 1993;177:195-200.
11. Maul-Pavicic A, Chiang SC, Rensing-Ehl A, et al. ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc Natl Acad Sci U S A. 2011;108:3324-3329.
12. Pores-Fernando AT, Zweifach A. Calcium influx and signaling in cytotoxic T-lymphocyte lytic granule exocytosis. Immunol Rev. 2009;231:160-173.
13. Tassi I, Presti R, Kim S, Yokoyama WM, Gilfillan S, Colonna M. Phospholipase C-γ2 is a critical signaling mediator for murine NK cell activating receptors. J Immunol. 2005;175:749-754.
14. Caraux A, Kim N, Bell SE, et al. Phospholipase C-γ2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells. Blood. 2006;107:994-1002.
15. Zanovello P, Rosato A, Bronte V, et al. Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis. J Exp Med. 1989;170:665-677.
16. Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol. 2011;12:218.
17. Nilius B, Biro T. TRPV3: a 'more than skinny' channel. Exp Dermatol. 2013;22:447-452.
18. Nilius B, Biro T, Owsianik G. TRPV3: time to decipher a poorly understood family member! J Physiol. 2014;592:295-304.
19. Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev. 2014;66:676-814.
20. Nilius B, Voets T. The puzzle of TRPV4 channelopathies. EMBO Rep. 2013;14:152-163.
21. Vennekens R, Menigoz A, Nilius B. TRPs in the brain. Rev Physiol Biochem Pharmacol. 2012;163:27-64.
22. Elhusseiny A, Hamel E. Muscarinic-but not nicotinic-acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J Cereb Blood Flow Metab. 2000;20:298-305.
23. Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem. 2000;43:4333-4353.
24. Oki T, Takagi Y, Inagaki S, et al. Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res. 2005;133:6-11.
25. Sharma G, Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci U S A. 2001;98:4148-4153.
26. Wess J, Duttaroy A, Zhang W, et al. M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels. 2003;9:279-290.
27. Beckmann J, Lips KS. The non-neuronal cholinergic system in health and disease. Pharmacology. 2013;92:286-302.
28. Lanzafame AA, Christopoulos A, Mitchelson F. Cellular signaling mechanisms for muscarinic acetylcholine receptors. Receptors Channels. 2003;9:241-260.
29. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol. 1996;10:69-99.
30. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160:221-227.
31. Allen J, Murray A, Di Maria C, Newton JL. Chronic fatigue syndrome and impaired peripheral pulse characteristics on orthostasis-a new potential diagnostic biomarker. Physiol Meas. 2012;33:231-241.
32. Brenu EW, Ashton KJ, van Driel M, et al. Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. J Affect Disord. 2012;141:261-269.
33. Brenu EW, Ashton KJ, Batovska J, Staines DR, Marshall-Gradisnik SM. High-throughput sequencing of plasma microRNA in chronic fatigue syndrome/myalgic encephalomyelitis. PloS One. 2014;9:e102783.
34. Brenu EW, Staines DR, Baskurt OK, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med. 2010;8:1.
35. Brenu EW, van Driel ML, Staines DR, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2012;10:88.
36. Brenu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011;9:81.
37. DeLuca J, Johnson SK, Beldowicz D, Natelson BH. Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. J Neurol Neurosurg Psychiatry. 1995;58:38-43.
38. Hoad A, Spickett G, Elliott J, Newton J. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. QJM. 2008;101:961-965.
39. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403-1410.
40. Lewis I, Pairman J, Spickett G, Newton JL. Clinical characteristics of a novel subgroup of chronic fatigue syndrome patients with postural orthostatic tachycardia syndrome. J Intern Med. 2013;273:501-510.
41. Medow MS, Stewart JM. The postural tachycardia syndrome. Cardiol Rev. 2007;15:67-75.
42. Nisenbaum R, Reyes M, Mawle AC, Reeves WC. Factor analysis of unexplained severe fatigue and interrelated symptoms: overlap with criteria for chronic fatigue syndrome. Am J Epidemiol. 1998;148:72-77.
43. Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol. 2005;142:505-511.
44. Marshall-Gradisnik S, Smith P, Nilius B, Staines DR. Examination of single nucleotide polymorphisms in acetylcholine receptors in chronic fatigue syndrome patients. Immunol Immunogenet Insights. 2015;7:7-20.
45. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953-959.
46. Marshall-Gradisnik SM, Smith P, Brenu EW, Nilius B, Ramos SB, Staines DR. Examination of single nucleotide polymorphisms (SNPs) in transient receptor potential (TRP) ion channels in chronic fatigue syndrome patients. Immunol Immunogenet Insights. 2015;2015:1-6.
47. Billeter AT, Hellmann JL, Bhatnagar A, Polk HC Jr. Transient receptor potential ion channels: powerful regulators of cell function. Ann Surg. 2014;259:229-235.
48. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87:165-217.
49. Lyubchenko TA, Wurth GA, Zweifach A. Role of calcium influx in cytotoxic T lymphocyte lytic granule exocytosis during target cell killing. Immunity. 2001;15:847-859.
50. Wang X, Schwarz TL. The mechanism of Ca2+-dependent regulation of kinesin-mediated mitochondrial motility. Cell. 2009;136:163-174.
51. Lykhmus O, Gergalova G, Koval L, Zhmak M, Komisarenko S, Skok M. Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int J Biochem Cell Biol. 2014;53:246-252.
52. Rah SY, Kwak JY, Chung YJ, Kim UH. ADP-ribose/TRPM2-mediated Ca2+ signaling is essential for cytolytic degranulation and antitumor activity of natural killer cells. Sci Rep. 2015;5:9482.
53. Kawashima K, Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther. 2000;86:29-48.
54. Kawashima K, Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci. 2003;72:2101-2109.
55. Kawashima K, Fujii T. Basic and clinical aspects of non-neuronal acetylcholine: overview of non-neuronal cholinergic systems and their biological significance. J Pharmacol Sci. 2008;106:167-173.
56. Kawashima K, Fujii T, Moriwaki Y, Misawa H. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. Life Sci. 2012;91:1027-1032.
57. Maliski W. Cholinergic receptors of lymphocytes. Brain Behav Immun. 1989;3:1-14.
58. Fujii T, Kawashima K. Calcium signaling and c-Fos gene expression via M3 muscarinic acetylcholine receptors in human T-and B-cells. Jpn J Pharmacol. 2000;84:124-132.
59. Fujii T, Kawashima K. YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-Fos gene expression mediated via muscarinic receptors in human T cells. Gen Pharmacol. 2000;35:71-75.
60. Fujii T, Harada H, Koyama T, Nakajima Y, Kawashima K. Effects of physostigmine and calcium on acetylcholine efflux from the hippocampus of freely moving rats as determined by in vivo microdialysis and a radioimmunoassay. Neurosci Lett. 2000;289:181-184.
61. Fujii T, Kawashima K. An independent non-neuronal cholinergic system in lymphocytes. Jpn J Pharmacol. 2001;85:11-15.
62. Kimura R, Ushiyama N, Fujii T, Kawashima K. Nicotine-induced Ca2+ signaling and down-regulation of nicotinic acetylcholine receptor subunit expression in the CEM human leukemic T-cell line. Life Sci. 2003;72:2155-2158.
63. Kawashima K, Fujii T. Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci. 2004;9:2063-2085.
64. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004;5:389-396.
65. Kuersten S, Goodwin EB. The power of the 3' UTR: translational control and development. Nat Rev Genet. 2003;4:626-637.
66. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol. 2003;10:120-125.
67. Fedor MJ. Alternative splicing minireview series: combinatorial control facilitates splicing regulation of gene expression and enhances genome diversity. J Biol Chem. 2008;283:1209-1210.
68. Crawford MH, Banerjee P, Demarchi DA, et al. Applications of pooled DNA samples to the assessment of population affinities: short tandem repeats. Hum Biol. 2005;77:723-733.
69. Shcherbakova I, Hoskins AA, Friedman LJ, et al. Alternative spliceosome assembly pathways revealed by single-molecule fluorescence microscopy. Cell Rep. 2013;5:151-165.
70. Lesch A, Hui X, Lipp P, Thiel G. Transient receptor potential melastatin-3 (TRPM3)-induced activation of AP-1 requires Ca2+ ions and the transcription factors c-Jun, ATF2, and ternary complex factor. Mol Pharmacol. 2015;87:617-628.
71. Frühwald J, Camacho Londoño J, Dembla S, et al. Alternative splicing of a protein domain indispensable for function of transient receptor potential melastatin 3 (TRPM3) ion channels. J Biol Chem. 2012;287:36663-36672.
72. Liu B, Qin F. Functional control of cold-and menthol-sensitive TRPM8 ion channels by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005;25:1674-1681.
73. McKemy DD. How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol Pain. 2005;1:16.
74. Park CK, Kim MS, Fang Z, et al. Functional expression of thermo-transient receptor potential channels in dental primary afferent neurons: implication for tooth pain. J Biol Chem. 2006;281:17304-17311.
75. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007;26:465-473.
76. Caseras X, Mataix-Cols D, Giampietro V, et al. Probing the working memory system in chronic fatigue syndrome: a functional magnetic resonance imaging study using the n-back task. Psychosom Med. 2006;68:947-955.
77. Caseras X, Mataix-Cols D, Rimes KA, et al. The neural correlates of fatigue: an exploratory imaginal fatigue provocation study in chronic fatigue syndrome. Psychol Med. 2008;38:941-951.
78. Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an 11C-(R)-PK11195 PET study. J Nucl Med. 2014;55:945-950